Salarius Pharmaceuticals (NASDAQ:SLRX) CFO Acquires 20,000 Shares

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) CFO Mark Rosenblum bought 20,000 shares of the firm’s stock in a transaction on Thursday, November 20th. The shares were purchased at an average cost of $0.80 per share, with a total value of $16,000.00. Following the completion of the transaction, the chief financial officer owned 20,177 shares in the company, valued at $16,141.60. This represents a 11,299.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Salarius Pharmaceuticals Trading Down 4.6%

Shares of SLRX traded down $0.04 during midday trading on Thursday, reaching $0.75. 708,648 shares of the stock were exchanged, compared to its average volume of 611,923. The company has a market capitalization of $382,245.00, a P/E ratio of -0.02 and a beta of 0.40. Salarius Pharmaceuticals, Inc. has a 52 week low of $0.71 and a 52 week high of $108.00. The company’s 50 day moving average is $3.61 and its two-hundred day moving average is $8.00.

Salarius Pharmaceuticals (NASDAQ:SLRX) last released its quarterly earnings data on Friday, November 14th. The company reported ($1.81) earnings per share for the quarter, beating the consensus estimate of ($33.60) by $31.79.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Salarius Pharmaceuticals to a “sell” rating in a research note on Friday, August 22nd.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.